Notably, HSP90 inhibitors, such as geldanamycin derivatives (e.g., 17-AAG and 17-DMAG) and resorcinol-based compounds (e.g., ganetespib), displayed potent anti-cancer activity in preclinical trials and are currently undergoing clinical trials evaluating their safety profiles. Here, HSP90AB1 is linked to cancer.